Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.

Ildiko Lingvay, Christopher B Granger, Jennifer B Green, Darren K McGuire, Laura Webb, Cagri Senyucel, Monica Levya, Caroline R Richardson, Rodica Pop-Busui, Jonathan Pak, Emily C O'Brien, Melissa L Magwire, Adam J Nelson, Julienne K Kirk, Lisa A Kaltenbach, Tanya Gaynor, Rogelio Braceras, Hussein R Al-Khalidi, Renato D Lopes, Matthew A Cavender, Vanita R Aroda, Maddalena Ardissino, Michelle D Kelsey, Neha J Pagidipati

Journal: American heart journal 2023;256():2-12

PMID: 36279931

Full Text on Elsevier Science View on PubMed

Abstract

Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, and system-level barriers all contribute to these gaps in care; yet, there is a paucity of high quality, rigorous studies evaluating the role of interventions to increase utilization. The COORDINATE-Diabetes trial randomized 42 cardiology clinics across the United States to either a multifaceted, site-specific intervention focused on evidence-based care for patients with T2DM or standard of care. The multifaceted intervention comprised the development of an interdisciplinary care pathway for each clinic, audit-and-feedback tools and educational outreach, in addition to patient-facing tools. The primary outcome is the proportion of individuals with T2DM prescribed three key classes of evidence-based medications (high-intensity statin, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and either a sodium/glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor or glucagon-like peptide 1 receptor agonist (GLP-1RA) and will be assessed at least 6 months after participant enrollment. COORDINATE-Diabetes aims to identify strategies that improve the implementation and adoption of evidence-based therapies.

Address: Duke Clinical Research Institute, Durham, NC.; Brigham and Women's Hospital, Boston, MA.; University of North Carolina, Chapel Hill, NC.; Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.; Wake Forest University School of Medicine, Winston Salem, NC.; University of Texas Southwestern Medical Center, Dallas, TX.; St Luke's Health System, Kansas MO.; University of Michigan Medical School, Ann Arbor, MI.; Eli Lilly and Company, Indiannapolis, IN.; University of Texas Southwestern Medical Center, Dallas, TX; Parkland Health and Hospital System, Dallas, TX.; Duke Clinical Research Institute, Durham, NC. Electronic address: [email protected].

DOI: 10.1016/j.ahj.2022.10.079

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetestype2.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Cardiology, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, United States, Cardiology Service, Hospital